Related Experiment Video
Updated: Aug 20, 2026
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
Prospects of antisense oligodeoxynucleotides to alleviate renal ischaemia-reperfusion injury
Masahide Matsuyama1, Rikio Yoshimura
1Osaka City University Graduate School of Medicine, Department of Urology, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.
Abstract:
Renal ischaemia-reperfusion (I/R) injury is a clinically significant problem and an invariable consequence of renal transplantation. The problem begins at the onset of acute tubular necrosis (ATN), when the transplantation takes a long ischaemic interval by using the cardiac arrest donor's kidney. In addition, the longer the ischaemic interval, the higher the incidence rate of ATN. It is clinically important that renal I/R injury is reduced. The antisense oligodeoxynucleotide (AS-ODN), developed as a therapy for intractable diseases at the gene level, has recently been established as an important method in examining specific gene functions. The authors have previously demonstrated that AS-ODN/tissue factor (TF) prevents renal I/R injury. This review discusses the efficacy of AS-ODN/TF and AS-ODN/intercellular adhesion molecule-1 as existing targets, and the potential of AS-ODN/nuclear factor-kappaB, AS-ODN/cyclooxygenase and AS-ODN/5-lipoxygenase as prospective targets.
Insights
Renal ischemia-reperfusion (I/R) injury is a major complication of kidney transplantation. Antisense oligodeoxynucleotides (AS-ODNs) targeting specific genes show promise in preventing this injury.
Area of Science:
- Nephrology
- Immunology
- Molecular Biology
Background:
- Renal ischemia-reperfusion (I/R) injury is a significant clinical issue in kidney transplantation.
- Prolonged ischemic intervals increase the incidence of acute tubular necrosis (ATN).
- Reducing renal I/R injury is crucial for successful transplantation outcomes.
Purpose of the Study:
- To review the efficacy of antisense oligodeoxynucleotides (AS-ODNs) in preventing renal I/R injury.
- To discuss existing and potential molecular targets for AS-ODN therapy.
- To explore AS-ODNs as a therapeutic strategy for renal I/R injury.
Main Methods:
- Review of existing literature on AS-ODN therapy for renal I/R injury.
- Discussion of AS-ODN targeting of tissue factor (TF) and intercellular adhesion molecule-1 (ICAM-1).
- Exploration of potential AS-ODN targets including nuclear factor-kappaB (NF-κB), cyclooxygenase (COX), and 5-lipoxygenase (5-LOX).
Main Results:
- AS-ODN/TF has been previously shown to prevent renal I/R injury.
- AS-ODN/ICAM-1 is an established target for mitigating I/R injury.
- AS-ODN targeting NF-κB, COX, and 5-LOX represents promising future therapeutic avenues.
Conclusions:
- AS-ODNs are effective in preventing renal I/R injury.
- Targeting specific genes with AS-ODNs offers a promising therapeutic approach for kidney transplantation.
- Further research into novel AS-ODN targets could significantly improve clinical outcomes.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...